{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05898620",
            "orgStudyIdInfo": {
                "id": "RTT-200"
            },
            "organization": {
                "fullName": "Neurogene Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Novel, Regulated Gene Therapy (NGN-401) Study for Female Children With Rett Syndrome",
            "officialTitle": "A Phase 1/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Pediatric Subjects With Rett Syndrome",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "a-novel-regulated-gene-therapy-ngn-study-for-female-children-with-rett-syndrome"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-13",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2029-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2029-10",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-06-01",
            "studyFirstSubmitQcDate": "2023-06-01",
            "studyFirstPostDateStruct": {
                "date": "2023-06-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-11",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-13",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Neurogene Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study will evaluate the safety profile of the investigational gene therapy, NGN-401, in female children with typical Rett syndrome.",
            "detailedDescription": "The study is a phase 1/2, open-label study designed to assess the safety, tolerability, and efficacy of administration of an adeno-associated viral vector serotype 9 (AAV9), using Neurogene's proprietary transgene regulation technology. NGN-401 contains a full-length human MECP2 gene which is designed to express therapeutic levels of the MECP2 protein while avoiding overexpression.\n\nThe study treatment will be administered under general anesthesia via intracerebroventricular (ICV) delivery. Each participant will be followed for safety and preliminary efficacy for 5 years after treatment and is expected to enroll in a long-term follow-up study for 10 years."
        },
        "conditionsModule": {
            "conditions": [
                "Rett Syndrome"
            ],
            "keywords": [
                "Typical Rett Syndrome",
                "MECP2",
                "Rett Disorder",
                "Genetic Diseases, Inborn",
                "Genetic Diseases, X-Linked",
                "Neurodevelopmental Disorders",
                "Neurobehavioral Manifestations",
                "Neurologic Manifestations",
                "Intellectual Disability",
                "Nervous System Diseases",
                "Heredodegenerative Disorders, Nervous System",
                "Pathologic Processes",
                "RTT"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 16,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Low Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Level 1",
                    "interventionNames": [
                        "Genetic: NGN-401"
                    ]
                },
                {
                    "label": "High Dose",
                    "type": "EXPERIMENTAL",
                    "description": "Dose Level 2",
                    "interventionNames": [
                        "Genetic: NGN-401"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "NGN-401",
                    "description": "NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene.",
                    "armGroupLabels": [
                        "High Dose",
                        "Low Dose"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment Emergent Adverse Events (TEAEs)",
                    "description": "Incidence, type, severity, and frequency of TEAEs",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Incidence of Serious Adverse Events (SAEs)",
                    "description": "Incidence, type, severity, and frequency of SAEs",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Incidence of Adverse Events of Special Interest (AESIs)",
                    "description": "Incidence, type, severity, and frequency of AESIs",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Incidence of clinical laboratory abnormalities",
                    "description": "Incidence, type, severity, and frequency of clinical laboratory abnormalities",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Incidence of new physical and neurologic exam abnormalities",
                    "description": "Incidence, type, severity, and frequency of new physical and neurologic exam abnormalities",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of typical Rett syndrome with a documented disease-causing mutation in the methyl-CpG-binding protein 2 (MECP2) gene\n* Current anti-epileptic drug regimen has been stable for at least 12 weeks\n* Participant and caregiver should reside within a 2-hour drive of the study center for at least 3 months following treatment\n* Participant must have never taken trofinetide or have taken trofinetide and discontinued due to tolerability, lack of efficacy, or other reasons. Following NGN-401 dosing, trofinetide may be initiated after a specified time period and with the support of the treating clinician\n\nExclusion Criteria:\n\n* Normal or near normal hand function\n* Has a current clinically significant condition other than Rett syndrome\n* Presence of a concomitant medical condition that precludes intracerebroventricular administration, or use of anesthetics needed for study related procedures\n* Grossly abnormal psychomotor development in the first 6 months of life\n* A history of other genetic disorders or neurological conditions, such as stroke, brain tumor, or autoimmune processes affecting the central nervous system\n\nOther inclusion or exclusion criteria apply.",
            "healthyVolunteers": false,
            "sex": "FEMALE",
            "genderBased": true,
            "minimumAge": "4 Years",
            "maximumAge": "10 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Contact Center",
                    "role": "CONTACT",
                    "phone": "+1 877-237-5020",
                    "email": "medicalinfo@neurogene.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Julie Jordan, MD",
                    "affiliation": "Neurogene Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Children's Hospital Colorado",
                    "status": "RECRUITING",
                    "city": "Aurora",
                    "state": "Colorado",
                    "zip": "80045",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "NeurogeneRettStudy@childrenscolorado.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.72943,
                        "lon": -104.83192
                    }
                },
                {
                    "facility": "Boston Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02115",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "617-355-5230",
                            "email": "rettresearch@childrens.harvard.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Texas Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "832-824-7729",
                            "email": "NeurogeneRettStudy@BCM.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000015518",
                    "term": "Rett Syndrome"
                },
                {
                    "id": "D000013577",
                    "term": "Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000004194",
                    "term": "Disease"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000038901",
                    "term": "Mental Retardation, X-Linked"
                },
                {
                    "id": "D000008607",
                    "term": "Intellectual Disability"
                },
                {
                    "id": "D000019954",
                    "term": "Neurobehavioral Manifestations"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                },
                {
                    "id": "D000040181",
                    "term": "Genetic Diseases, X-Linked"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                },
                {
                    "id": "D000020271",
                    "term": "Heredodegenerative Disorders, Nervous System"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "asFound": "Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11589",
                    "name": "Intellectual Disability",
                    "relevance": "LOW"
                },
                {
                    "id": "M30644",
                    "name": "Neurodevelopmental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "M21826",
                    "name": "Neurobehavioral Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "M18163",
                    "name": "Rett Syndrome",
                    "asFound": "Rett Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22092",
                    "name": "Heredodegenerative Disorders, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M24877",
                    "name": "Genetic Diseases, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "M24774",
                    "name": "Mental Retardation, X-Linked",
                    "relevance": "LOW"
                },
                {
                    "id": "T4987",
                    "name": "Rett Syndrome",
                    "asFound": "Rett Syndrome",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}